核心观点AK112 联合化疗对比替雷利珠单抗联合化疗一线治疗晚期sq-NSCLC 达到PFS 的主要研究终点,研究结果具有统计学显著获益和重大临床获益,填补了抗血管生成机制药物在sq-NSCLC 中的空白,推动依沃西实现了在NSCLC 领域一线和后线治疗更全面的布局,再次验证双靶点的巨大潜力。未来可以关注:(1)依沃西单抗国内1L PD-L1 阳性NSCLC 适应症的获批;(2)卡度尼利单抗宫颈癌...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.